YAP1 and lung adenocarcinoma: Moreover, lung adenocarcinoma patients with higher coexpression of CD109 and YAP showed worse overall and disease-specific survival probabilities (Figure 6C), underpinning the potential role of CD109 possibly serving as prognostic and therapeutic targets for lung adenocarcinoma patients.